Alpha 0.1.0

Biotech411

Biotechnology. Right now.

All programs

Rare disease

Fayuvi · Sanfilippo syndrome type A

Approved · As of

Study NCT02716246 was one of three records FDA cited in its review of Fayuvi for children with preserved neurodevelopmental function.

Milestone history

  1. The treatment study (NCT02716246) began.

    ClinicalTrials.gov
  2. FDA licensed Fayuvi to treat neurological manifestations of pediatric Sanfilippo syndrome type A in the indicated population.

    FDA